ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200-Day Moving Average – Should You Sell?

ImmuCell Co. (NASDAQ:ICCC) crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $4.67 and traded as high as $5.55. ImmuCell shares last traded at $5.50, with a volume of 6,002 shares traded.

ImmuCell Stock Performance

The company has a current ratio of 3.11, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $49.41 million, a price-to-earnings ratio of -11.00 and a beta of 0.39. The stock’s 50 day moving average price is $5.12 and its two-hundred day moving average price is $4.67.

ImmuCell (NASDAQ:ICCC) last posted its earnings results on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a negative net margin of 15.99% and a negative return on equity of 15.32%. The firm had revenue of $7.75 million during the quarter.

Hedge Funds Weigh In On ImmuCell

A number of institutional investors have recently made changes to their positions in ICCC. Dauntless Investment Group LLC purchased a new position in shares of ImmuCell during the fourth quarter valued at approximately $676,000. Geode Capital Management LLC raised its position in shares of ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock worth $332,000 after buying an additional 7,878 shares during the period. Northern Trust Corp boosted its holdings in ImmuCell by 51.0% in the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 14,982 shares during the last quarter. Citadel Advisors LLC purchased a new stake in ImmuCell during the fourth quarter valued at about $149,000. Finally, Mesirow Financial Investment Management Inc. lifted its position in ImmuCell by 100.0% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 12,178 shares in the last quarter. 13.47% of the stock is owned by institutional investors and hedge funds.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.